EASL 临床实践指南 : 丙型肝炎病毒感染的管理。
关键词: AE ALT BMI BOC BT CPGs CYP3A4 Clinical Practice Guidelines DAA DVR EIA EPO EVR G-CSF GRADE Grading of Recommendations Assessment, Development and Evaluation HBV HCC HCV IDU IFN IU LSM LT OST PI PWID PegIFN/RBV RVR SCAR SVR TSH TVR adverse event alanine aminotransferase boceprevir body mass index cytochrome p450 3A4 delayed virological response direct-acting antiviral eRVR early virological response enzyme immunoassays erythropoietin extended rapid virological response granulocyte colony stimulating factor hepatitis B virus hepatitis C virus hepatocellular carcinoma interferon international units intravenous/injecting drug use liver stiffness measurement liver transplant opiate/opioid substitution treatment/therapy pegylated interferon-α and ribavirin people who inject drugs protease inhibitor rapid virological response severe cutaneous adverse reaction sustained virological response telaprevir thyroid stimulating hormone viral breakthrough
Mesh : Antiviral Agents / administration & dosage therapeutic use Contraindications Drug Monitoring Drug Therapy, Combination Genotype Hepacivirus / genetics Hepatitis C / drug therapy etiology virology Humans Interferon-alpha / therapeutic use Liver Cirrhosis / drug therapy Oligopeptides / therapeutic use Proline / analogs & derivatives therapeutic use Ribavirin / therapeutic use
来 源:
DOI:10.1016/j.jhep.2013.11.003
PDF(Sci-hub)